Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Renal osteodystrophy:

Renal Osteodystrophy-Time for Common Nomenclature. Ott SM et al. Curr Osteoporos Rep. (2017)

Renal Osteodystrophy or Kidney-Induced Osteoporosis? Moe SM et al. Curr Osteoporos Rep. (2017)

Emerging role of high-resolution imaging in the detection of renal osteodystrophy. Sharma AK et al. Nephrology (Carlton). (2016)

Search results

Items: 1 to 20 of 4696

1.

[Specific cases of slipped capital femoral epiphysis : Endocrinopathies, hormone therapy and other rare causes].

Wirth T, Eberhardt O, Cerkez D, Fernandez F.

Orthopade. 2019 Apr 17. doi: 10.1007/s00132-019-03728-3. [Epub ahead of print] Review. German.

PMID:
30997550
2.

Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients
.

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T.

Clin Nephrol. 2019 Apr 16. doi: 10.5414/CN109723. [Epub ahead of print]

PMID:
30990412
3.

Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease.

Ureña-Torres PA, Vervloet M, Mazzaferro S, Oury F, Brandenburg V, Bover J, Cavalier E, Cohen-Solal M, Covic A, Drüeke TB, Hindié E, Evenepoel P, Frazão J, Goldsmith D, Kazama JJ, Cozzolino M, Massy ZA; ERA-EDTA CKD-MBD Working Group.

Clin Kidney J. 2018 Jul 20;12(2):269-280. doi: 10.1093/ckj/sfy061. eCollection 2019 Apr.

4.

The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.

Li J, Wang L, Han M, Xiong Y, Liao R, Li Y, Sun S, Maharjan A, Su B.

Nutr Diabetes. 2019 Apr 3;9(1):14. doi: 10.1038/s41387-019-0080-2. Review.

5.

Association of Mineral Content Outside of Bone with Coronary Artery Calcium and 1-Year Cardiovascular Prognosis in Maintenance Hemodialysis Patients.

Xiong Y, Li J, Sun S, Han M, Liao R, Li Y, Wang L, Lin L, Liu Q, Su B.

Artif Organs. 2019 Apr 1. doi: 10.1111/aor.13461. [Epub ahead of print]

PMID:
30932185
6.

A mathematical model of parathyroid gland biology.

Schappacher-Tilp G, Cherif A, Fuertinger DH, Bushinsky D, Kotanko P.

Physiol Rep. 2019 Apr;7(7):e14045. doi: 10.14814/phy2.14045.

7.

Hyperchloremic metabolic acidosis in the kidney transplant patient.

Avila-Poletti D, De Azevedo L, Iommi C, Heldal K, Musso CG.

Postgrad Med. 2019 Apr;131(3):171-175. doi: 10.1080/00325481.2019.1592360. Epub 2019 Mar 29. Review.

PMID:
30924703
8.

Authors' Reply.

Marques IDB, Elias RM, Moysés RMA, David-Neto E.

J Am Soc Nephrol. 2019 Mar 25. pii: ASN.2019020124. doi: 10.1681/ASN.2019020124. [Epub ahead of print] No abstract available.

PMID:
30910936
9.

Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation.

Tabibzadeh N, Chavarot N, Flamant M, Vidal-Petiot E.

J Am Soc Nephrol. 2019 Mar 25. pii: ASN.2019010079. doi: 10.1681/ASN.2019010079. [Epub ahead of print] No abstract available.

PMID:
30910935
10.

Chronic Kidney Disease and Pulse Wave Velocity: A Narrative Review.

Lioufas N, Hawley CM, Cameron JD, Toussaint ND.

Int J Hypertens. 2019 Feb 17;2019:9189362. doi: 10.1155/2019/9189362. eCollection 2019. Review.

11.

Radiographic manifestations of abnormal bone and mineral metabolism in end-stage renal disease.

Koratala A, Morales Lappot J, Kazory A.

Clin Case Rep. 2019 Feb 7;7(3):589-590. doi: 10.1002/ccr3.2043. eCollection 2019 Mar.

12.

Neutrophil-to-lymphocyte ratio and incident end-stage renal disease in Chinese patients with chronic kidney disease: results from the Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE).

Yuan Q, Wang J, Peng Z, Zhou Q, Xiao X, Xie Y, Wang W, Huang L, Tang W, Sun D, Zhang L, Wang F, Zhao MH, Tao L, He K, Xu H; C-STRIDE study group.

J Transl Med. 2019 Mar 15;17(1):86. doi: 10.1186/s12967-019-1808-4.

13.

Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.

Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH.

Clin Nephrol. 2019 Apr;91(4):222-230. doi: 10.5414/CN109650.

PMID:
30862350
14.

Musculoskeletal manifestations in end-stage renal disease patients on hemodialysis and relation to parathyroid dysfunction.

Afifi WM, Abo Elsaoud AM, Elgawish MH, Ghorab AM.

Saudi J Kidney Dis Transpl. 2019 Jan-Feb;30(1):68-82.

PMID:
30804269
15.

The use of LP533401 as a therapeutic option for renal osteodystrophy affects, renal calcium handling, vitamin D metabolism, and bone health in uremic rats.

Pawlak D, Domaniewski T, Znorko B, Pawlak K.

Expert Opin Ther Targets. 2019 Apr;23(4):353-364. doi: 10.1080/14728222.2019.1586883. Epub 2019 Mar 12.

PMID:
30801205
16.

Osteoporosis, bone mineral density and CKD-MBD (II): Therapeutic implications.

Bover J, Ureña-Torres P, Laiz Alonso AM, Torregrosa JV, Rodríguez-García M, Castro-Alonso C, Górriz JL, Benito S, López-Báez V, Lloret Cora MJ, Cigarrán S, DaSilva I, Sánchez-Bayá M, Mateu Escudero S, Guirado L, Cannata-Andía J.

Nefrologia. 2019 Feb 20. pii: S0211-6995(19)30012-8. doi: 10.1016/j.nefro.2018.10.009. [Epub ahead of print] Review. English, Spanish.

17.

Regional prescription surveillance of phosphate binders in the western Saitama area: the substantial role of ferric citrate hydrate in improving serum phosphorus levels and erythropoiesis.

Amano H, Ohno Y, Inoue T, Tomori K, Ohama K, Okada H.

Clin Exp Nephrol. 2019 Feb 19. doi: 10.1007/s10157-019-01715-8. [Epub ahead of print]

PMID:
30783915
18.

Dysregulated Phosphate Metabolism, Periodontal Disease, and Cancer: Possible Global Health Implications.

Brown RB.

Dent J (Basel). 2019 Feb 11;7(1). pii: E18. doi: 10.3390/dj7010018.

19.

Hypercalcitoninaemia in pseudohypo-parathyroidism type 1A and type 1B.

Yavropoulou MP, Chronopoulos E, Trovas G, Avramidis E, Elli FM, Mantovani G, Zebekakis P, Yovos JG.

Endocrinol Diabetes Metab Case Rep. 2019 Jan 31;2019. pii: EDM180125. doi: 10.1530/EDM-18-0125. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center